| Name | Title | Contact Details |
|---|
Practical Applications is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresite Labs incubates companies that will address some of our greatest unmet medical needs. Their experienced team of scientists, engineers, and operators believes that the tools of data science, when applied with scientific rigor, will greatly accelerate scientific discovery and the development of new products and services that benefit patients. Through its incubation platform, Foresite Labs is dismantling the barriers faced by visionary entrepreneurs and their companies as they seek to re-invent healthcare. Foresite Labs Values Truth over progression: We follow the science, pursuing ideas that are grounded in data and abandoning them when not supported by the evidence. Take good risks: Our culture values informed risk-taking: good decisions are celebrated even when they result in bad outcomes. Everyone feels safe to contribute ideas and to learn from failure. Single accountable person: The project team lead is accountable for all decisions and for maintaining transparency and information flow within the team; we trust the project teams. The Review Committee unlocks capital and sets directions. Simplicity and Focus: Companies die from indigestion, not starvation (Bill Hewlett) We will focus on a few ideas aggressively and minimize all other distractions. Everyone will have a few key goals that have measurable outcomes. Respect and Community: Our employees are our greatest asset; everyone invests in creating an environment of collaboration and respect. We support their careers and career development whether they stay, go to a Labs company, or end up somewhere else.
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Our shared purpose to serve patients in need drives us to find answers, change the world, and create a legacy. Alexion`s three highly innovative therapies treat patients with four severe and ultra-rare diseases, and we are committed to developing additional therapies that have the potential to transform patients` lives. Today, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs across a range of therapeutic modalities. Alexion has more than 3,000 employees serving patients in 50 countries. Our global headquarters and research operations are based in New Haven, Connecticut and our EMEA headquarters are in Zürich, Switzerland. We also have global supply chain and operations headquarters in Ireland, manufacturing facilities in the United States, and local and regional operations in countries around the world. Alexion was ranked number 5 by Science magazine in its Top Employer Survey and has also been ranked as one of the top companies on the Forbes "World`s Most Innovative Companies" list every year since 2012.
Greiner Bio One Inc is a Monroe, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our founding belief is that the future of medicine will rely on artificial intelligence, because biology is too complex for humans to understand. Today, the molecular world of the cell can be experimentally interrogated like never before. The resulting datasets provide an unprecedented opportunity to build artificial intelligence systems that are biologically accurate and that support the detection of disease and the development of molecular interventions. Deep Genomics is building a biologically accurate data- and AI-driven platform that supports geneticists, molecular biologists and chemists in the development of therapies. Over the next two years, Deep Genomics will use its platform to unlock new classes of antisense oligonucleotide therapies that were previously inaccessible or out of reach, and advance them for clinical evaluation. In project Saturn, the platform will be used to search across a vast space of over 69 billion molecules with the goal of generating a library of 1000 compounds that can be used to manipulate cell biology and design therapies.